<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911222</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-143</org_study_id>
    <secondary_id>IOM-143</secondary_id>
    <nct_id>NCT00911222</nct_id>
  </id_info>
  <brief_title>Epidemiological EMESIS-Registry</brief_title>
  <acronym>EMESIS</acronym>
  <official_title>Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASORS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <brief_summary>
    <textblock>
      The purpose of this registry is to record information on reality of anti-emetic therapies of
      cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic
      therapies dependent on the rate &quot;complete and major control&quot; of nausea and emesis in
      moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin,
      carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of anti-emetic therapies dependent on the rate &quot;complete and major control&quot; of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.</measure>
    <time_frame>4 chemotherapy applications per patient</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1035</enrollment>
  <condition>Antiemetic Therapy</condition>
  <arm_group>
    <arm_group_label>antiemetic treatment</arm_group_label>
    <description>epidemiological registry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional</description>
    <arm_group_label>antiemetic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Practitioners specialized in oncology, hematology and/or gynaecology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderately or highly emetogenic chemotherapy consisting of platin-derivates
             (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

          -  start with the 1st cycle of the regimen (chemo naive patients). Inclusion of
             pretreated patients is also possible, if the last treatment cycle of a previous
             chemotherapy was given &gt;= 24 months ago.

          -  Compliance with registry procedures

          -  Age &gt;= 18 years

          -  WHO Performance Status of 0 or 1 (Karnofsky-Index &gt;= 70%)

          -  Life expectancy of at least 12 weeks

          -  Signed and dated informed consent before the start of the registry

        Exclusion Criteria:

          -  Mentally incapable or incompliant patients

          -  Last chemotherapy &lt;= 24 months (if pretreated)

          -  Known hypersensitivity to antiemetic medication

          -  unability of the patient to be treated with oral medication

          -  pregnancy or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Schröder, Dr. med. / MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis für Hämatologie und Onkologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iOMEDICO AG</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006 Jun 20;24(18):2932-47. Epub 2006 May 22. Erratum in: J Clin Oncol. 2006 Nov 20;24(33):5341-2.</citation>
    <PMID>16717289</PMID>
  </reference>
  <reference>
    <citation>MASCC guidelines: Consensus Conference on Antiemetic Therapy, Perugia, march 29 - 31. 2004, update: December 2007)</citation>
  </reference>
  <reference>
    <citation>Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology. 1996 Jun;53 Suppl 1:92-5.</citation>
    <PMID>8692559</PMID>
  </reference>
  <reference>
    <citation>Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med. 1981 Oct 15;305(16):948-9.</citation>
    <PMID>7278899</PMID>
  </reference>
  <reference>
    <citation>Gralla RJ. Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res. 1991;121:68-85. Review.</citation>
    <PMID>1857886</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiemetic therapy</keyword>
  <keyword>emesis</keyword>
  <keyword>vomiting</keyword>
  <keyword>nausea</keyword>
  <keyword>moderately and highly emetogenic chemotherapy</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>anthracycline</keyword>
  <keyword>cyclophosphamid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

